MarketLens
Sign Up

What's Behind the Recent Insider Selling at AnaptysBio

5 months ago
SHARE THIS ON:

What's Behind the Recent Insider Selling at AnaptysBio

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News6 days ago

Insider Confidence Is Building in These 3 Very Different Stocks

Insider buying is rising in three unnamed stocks after share-price weakness, signaling possible confidence from CEOs or controlling shareholders. The pattern may offer a useful, though imperfect, sign...
Stock News1 months ago

AnaptysBio: The Royalty Waterfall Is About To Reverse

AnaptysBio's value now hinges on Jemperli royalties from GSK, with a 95% targeted EBIT margin and over $140M net cash. Royalty retention will rise after the Sagard obligation is paid by mid-2027.
Stock News2 months ago

MoonLake Immunotherapeutics' CFO Sells 39K Shares

MoonLake Immunotherapeutics' CFO sold 39,000 shares, a notable insider transaction at the clinical-stage Nanobody therapy company.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Did Nvidia Just Say Checkmate to AMD and Intel?

Stock News4 hours ago

Amazon cargo plane overshoots runway at Miami airport

Stock News4 hours ago

Amazon Prime Air Boeing 767 overruns runway at Miami airport

Stock News4 hours ago

Could $10,000 Invested in Nvidia Today Make You a Millionaire?

Stock News6 hours ago

Nvidia Is Near Its High While Its Biggest Chip Peers Sit 18% to 32% Below Theirs. These Are the Chip Stocks to Buy.